The development of immune-checkpoint inhibitors (ICIs) has heralded a new era in cancer
treatment, enabling the possibility of long-term survival in patients with metastatic disease …

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which
involve diverse organs, have varying biology, onset time, and severity. Herein, we identify …

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …

Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are
associated with a unique spectrum of organ-specific inflammatory toxicities known as …

Immune checkpoint inhibitors, a class of oncological treatments that enhance antitumour
immunity, can trigger neurological adverse events closely resembling paraneoplastic …

Background Immune-related adverse events (irAEs) are a common phenomenon in cancer
patients treated with immune checkpoint inhibitors (ICIs). Surprisingly, the toxicity burdens of …

While the spectrum of neurological immune checkpoint inhibitor-related adverse events is
expanding, patients' outcomes are not well documented. This study aimed to assess …

Background Neurological immune-related adverse events (irAE-n) are severe and
potentially fatal toxicities of immune checkpoint inhibitors (ICI). To date, the clinical …

Background and Objectives To clinically characterize post–immune checkpoint inhibitor (ICI)
Hu antibody (Ab) neurologic disorders, we analyzed Hu-Ab–positive patients with …

Glioblastoma (GBM) tumors are the most aggressive primary brain tumors in adults that,
despite maximum treatment, carry a dismal prognosis. GBM tumors exhibit tissue hypoxia …